Ultragenyx (RARE) director receives RSU and stock option grants

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical Inc. director Sanders Corazon (Corsee) D. received new equity awards as part of compensation. On May 14, 2026, the director acquired 7,751 shares of common stock through an award of restricted stock units under the company’s 2023 Incentive Plan, bringing direct holdings to 23,095 shares.

On the same date, the director was granted a stock option for 14,058 shares of common stock at an exercise price of $25.80 per share, expiring on May 14, 2036. Both the RSUs and the option vest in full on the earlier of the company’s next annual meeting of stockholders or May 14, 2027, making these routine, time-based equity incentives rather than open-market purchases.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Sanders Corazon (Corsee) D.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	14,058	$0.00	--
Grant/Award	Common Stock	7,751	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 14,058 shares (Direct, null); Common Stock — 23,095 shares (Direct, null)

Footnotes (1)

Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

Key Figures

RSU award: 7,751 shares Option grant size: 14,058 shares Option exercise price: $25.80 per share +4 more

7 metrics

RSU award 7,751 shares Restricted Stock Units granted May 14, 2026

Option grant size 14,058 shares Stock Option (Right to Buy) granted May 14, 2026

Option exercise price $25.80 per share Exercise price of new stock option

Option expiration May 14, 2036 Expiration date of stock option grant

Director holdings after RSU grant 23,095 shares Total common shares directly held after award

RSU vesting date Earlier of next annual meeting or May 14, 2027 Vesting condition for RSU award

Option vesting date Earlier of next annual meeting or May 14, 2027 Vesting condition for stock option

Key Terms

Restricted Stock Units ("RSUs"), 2023 Incentive Plan, Stock Option (Right to Buy), Annual Meeting of Stockholders

4 terms

Restricted Stock Units ("RSUs") financial

"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2023 Incentive Plan financial

"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) listed as a derivative security."

Annual Meeting of Stockholders financial

"The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027."

Form 4 Insider Transactions: What Each Field Means →

05/18/2026 - 06:38 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sanders Corazon (Corsee) D.

(Last)

(First)

(Middle)

C/O ULTRAGENYX PHARMACEUTICAL INC.

60 LEVERONI COURT

(Street)

NOVATO

CALIFORNIA

94949

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/14/2026		A		7,751⁽¹⁾	A	$0	23,095	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$25.8	05/14/2026		A		14,058		⁽²⁾	05/14/2036	Common Stock	14,058	$0	14,058	D

Explanation of Responses:

1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

2. The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

	/s/ Karah Parschauer, attorney-in-fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Ultragenyx (RARE) director Sanders Corazon receive?

The director received 7,751 restricted stock units and a stock option for 14,058 shares at $25.80 per share. Both awards are compensation grants, not market purchases, tied to continued board service and future vesting.

When do the new Ultragenyx (RARE) RSUs and options for the director vest?

Both the 7,751 RSUs and the 14,058-share stock option vest in full on the earlier of Ultragenyx’s next annual meeting of stockholders or May 14, 2027. Vesting depends on the director remaining in service through that date.

What is the exercise price and expiration for the Ultragenyx (RARE) director’s new option?

The stock option covers 14,058 shares of common stock at an exercise price of $25.80 per share. It expires on May 14, 2036, giving the director a long-dated right to buy shares once the option is vested.

How many Ultragenyx (RARE) shares does the director hold after the RSU award?

Following the RSU grant, the director directly holds 23,095 shares of Ultragenyx common stock. This total reflects the effect of the 7,751-share restricted stock unit award reported in the same filing as a compensation-related acquisition.

Are the Ultragenyx (RARE) director’s equity awards open-market purchases?

No, both the 7,751-share RSU award and the 14,058-share stock option are compensation grants. They were issued under Ultragenyx’s 2023 Incentive Plan and vest based on future service, rather than being shares bought on the open market.